Loading…
Loading…
MONTSAME

On February 9, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of Mongolia.
The vaccine was approved under the emergency use authorization procedure without additional clinical trials in the country. The EUA was obtained with the assistance from RDIF's local partner Mongol Emimpex Concern LLC, the country's leading pharmaceutical company.
Mongolia has become the 23rd country in the world to approve Sputnik V. The vaccine had been approved earlier in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar and Pakistan.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund said “Partners in Mongolia decided to authorize the vaccine after conducting a thorough review of the data of Sputnik V clinical trial demonstrating its high efficacy and safety as confirmed by the publication in The Lancet magazine. Sputnik V is one of the leading vaccines in the world and the number of registrations of the vaccine keeps growing day by day.”
Sputnik V has a number of key advantages:
source: Russian Direct Investment Fund